Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Fedratinib reduced spleen size and symptoms in ruxolitinib-pretreated myelofibrosis patients in FREEDOM2 trial.
PXS-5505 shows promise in ruxolitinib-refractory myelofibrosis, improving symptoms and reducing bone marrow fibrosis.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Ruchi Desai, MD, specifies what improvements are needed today in the therapy options available for myelofibrosis.
Ruchi Desai, MD, speaks on the challenges of clinical evaluation and therapy optimization in myelofibrosis.
From Buffalo to the Manhattan borough, Dr. Rampal shares his journey to becoming a hematologist-oncologist.
Nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, showed clinical activity in a phase 1/2 study.
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
End Point Success Varies in a Phase 3 Trial of Luspatercept Plus JAK Inhibitor Therapy for MF Anemia
The combination did not meet the primary end point for RBC transfusion independence but still markedly improved anemia.
The agent, nuvisertib, previously received Orphan Drug Designation from the FDA for this indication in May 2022.
Gecacitinib improved spleen volume, symptoms, and anemia in JAK inhibitor–naive MF, regardless of baseline anemia severity.
The MANIFEST-2 trial compares pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAK-inhibitor-naive myelofibrosis.
Experts discuss patient-centered approaches and novel therapies reshaping MF treatment in a roundtable.
Experts explore anemia therapies, JAK inhibitors, and transplant innovations shaping the promising future of MF care.
Experts discuss molecular insights into MF, highlighting mutations, risk assessment, and evolving therapeutic approaches.
Experts discuss current treatments and ongoing research in myelofibrosis, highlighting new therapies and clinical trials.
Experts discuss CALR-targeting therapies, symptom assessment, and the future of myelofibrosis treatment and regulation.
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.